Creative Diagnostics launches custom ELISA kit development services

Creative Diagnostics has introduced custom ELISA kit development services for biotechnology companies, pharmaceutical laboratories, and academic researchers. The offering is designed to speed up development of sensitive, reproducible immunoassays for target analytes and support moves from research use only to in vitro diagnostics.

Why it matters: - Creative Diagnostics is targeting demand for custom immunoassay development across biopharma, diagnostics, and academic research. - The service is aimed at helping researchers build validated ELISA kits for specific analytes with higher sensitivity and reproducibility. - The offering also supports users who want to transition assays from research use only to in vitro diagnostics.

What happened: - Creative Diagnostics announced the launch of comprehensive ELISA Kit Development services on July 27, 2026. - The service is designed for biotechnology companies, pharmaceutical laboratories, and academic institutions. - The company says the new offering covers antibody matched pair screening, precision automated microplate coating, and positive control antibody development. - Creative Diagnostics provided a full service overview for researchers seeking project consultations.

The details: - The service covers the full ELISA development workflow, from antigen design and synthesis to antibody screening, assay development and optimization, microplate coating, and complete kit production. - Each kit undergoes development and validation to support detection and quantification of specific target analytes. - The company says the kits are intended to be highly sensitive, reproducible, and fully validated. - Creative Diagnostics says its research team has extensive experience in custom antibody development and antibody preparation for targets ranging from small molecules to large proteins. - The company says its scientists have developed hundreds of unique diluents and have decades of experience optimizing analytical conditions. - The services can support drug discovery and development, including pharmacokinetics, anti-drug antibodies, and clinical sample screening. - The offering also covers industrial process control, diagnostic biomarker test kits, vaccine quality control and efficacy assessment, food, water, and environmental testing, small-molecule drug monitoring, and target expression validation in cell lines or extracts. - The company says it can help users move assays from RUO to IVD platforms.

Between the lines: - The launch reflects continued demand for custom assay development as researchers look for test formats tailored to specific targets and workflows. - Creative Diagnostics is positioning ELISA development as a broader platform service, not just a single kit product. - The company is also signaling that automation and validation are becoming more important in research and diagnostic workflows.

What's next: - Researchers can request project consultations through Creative Diagnostics' ELISA service page. - The company is likely to use the new service to expand its role in assay development, kit production, and diagnostic support. - Further adoption will depend on how well the service meets turnaround, validation, and customization needs across different applications.

The bottom line: - Creative Diagnostics is betting that custom, validated ELISA development will remain a core need for labs building targeted research and diagnostic assays.